Immuno-oncology is not a new frontier, and for years, therapies like checkpoint inhibitors have reshaped how we treat certain cancers. While early approaches established that the immune system could fight cancer, the field has seen both major breakthroughs and clear limitations. Drugs like Keytruda proved that checkpoint blockade could work, but they also exposed clear limits, especially in certain cancers where many patients fail to respond or eventually relapse.
For decades, cancer treatment followed a relatively straightforward progression. Patients typically received surgery, radiation, chemotherapy, or some combination of these modalities depending on the type and stage of disease. While these treatments have saved countless lives, they share a major drawback if the cancer spreads (metastasizes). In this setting surgery is usually not practical and radiation has limited use. Chemotherapy, by destroying healthy cells alongside cancer cells, causes severe side effects and fails to train the body to prevent a relapse due to their focus on attacking the tumor directly rather than using the body’s own defenses to fight back.
Personalized cancer care has already proven what is possible, particularly with autologous cell therapies that engineer a patient’s own cells. However, these custom approaches face steep hurdles, including long manufacturing delays, high costs, and difficulty penetrating solid tumors. The next shift in oncology is about overcoming those limits. The goal now is combining the power of personalized immune matching with scalable, off-the-shelf therapies that can reach more patients quickly without sacrificing precision.
This next generation of care relies on the convergence of personalized medicine and immunology. By matching a patient’s unique biological profile with therapies that actively present tumor targets, scientists are working to make immunotherapies effective for a much wider range of patients.
Overcoming these barriers requires off-the-shelf strategies that deliver personalized, targeted immune activation without custom manufacturing delays. Modern approaches are increasingly turning to engineered cell platforms matched to specific tissue types that present targets directly to the immune system. Combining targeted antigen presentation with active stimulation can convert “cold” tumors into hot targets, bringing scalable precision to cancer care.
Why Cancer Remains So Difficult to Treat
Cancer is extraordinarily complex because it is not one disease. Every tumor develops its own genetic profile, biological behavior, and mechanisms for evading immune detection. Two patients diagnosed with the same type of cancer may respond very differently to identical treatments. And cancer cells, which arise by mutation, continue to mutate so that even within one patient multiple different mutated cancer cells are present.
One of cancer’s greatest strengths is its ability to suppress immune activity. Tumors often create a microenvironment that prevents immune cells from recognizing or attacking malignant tissue. Cancers also can actively exploit normal immune checkpoints designed to prevent excessive inflammation, effectively hiding in plain sight.
These escape mechanisms help explain why conventional therapies and early immunotherapies may lose effectiveness over time and why many advanced cancers remain difficult to control despite significant therapeutic advances.
Fortunately, growing knowledge of tumor immunology is providing researchers with entirely new strategies for overcoming these barriers.
Immunotherapy Changed the Conversation, But Gaps Remain
Immune checkpoint inhibitors demonstrated that releasing the immune system’s natural “brakes” could produce durable responses in diseases such as melanoma, lung cancer, kidney cancer, and several other malignancies. Some patients have experienced long-term disease control that would have been difficult to imagine only twenty years ago.
Checkpoint inhibitors also changed how scientists think about the disease. Instead of just looking for stronger drugs to kill cancer, researchers realized the immune system could be a powerful tool on its own.
Yet immunotherapy has also highlighted an important reality: not every patient responds.
Even with treatment, many tumors remain immunologically “cold,” meaning they attract few active immune cells capable of mounting an effective anti-tumor response. Others initially respond before developing resistance through additional immune escape mechanisms. This is particularly evident in breast cancer, where checkpoint inhibitors have historically shown limited success on their own due to the complex tumor microenvironment and immune evasion tactics.
These challenges have prompted the next generation of innovation.
Cell Therapy Is Expanding the Possibilities
Cell therapies and targeted cellular approaches are expanding cancer treatment by putting living cells and cell-derived platform technologies, rather than traditional drugs, at the center of care.
The best-known examples are CAR-T cell therapies, which involve collecting a patient’s T cells, genetically engineering them to recognize specific cancer targets, expanding those cells, and reinfusing them into the patient. CAR-T therapies have produced remarkable clinical outcomes in several blood cancers and demonstrated that living medicines can fundamentally change treatment paradigms. However, adapting these successes to solid tumors, including breast cancer, presents distinct biological hurdles.
Making the case for immuno-oncology in breast cancer requires moving beyond one-size-fits-all solutions. Advanced breast cancers often suppress immune recognition, making it critical to find novel ways to present tumor antigens directly to the patient’s immune system.
At the same time, researchers are exploring a much broader spectrum of cell-based approaches.
Some strategies utilize tumor-infiltrating lymphocytes (TILs), which isolate naturally occurring immune cells already present within tumors and expand them outside the body before reinfusion. Others investigate natural killer (NK) cells, dendritic cell vaccines, engineered immune cells, and novel allogeneic cell platforms designed to stimulate broader immune activation.
Instead of relying on a single mechanism, these therapies work by helping the body naturally recognize cancer as a threat.
This evolution reflects a broader realization that successful treatment often requires activating multiple components of the immune response rather than targeting only one pathway.
Personalization Is Becoming More Sophisticated
Personalized oncology used to be mostly about mapping a tumor’s DNA to find specific genetic mutations. While testing genes is still vital, personalizing cancer care now goes far beyond looking at genetics.
Researchers now examine immune biomarkers, tissue type matching, cytokine signaling, antigen presentation, immune cell infiltration, circulating tumor DNA, and the characteristics of the tumor microenvironment.
Artificial intelligence and advanced computational biology are also accelerating this process. Machine learning models can integrate vast biological datasets that would be impossible for clinicians to evaluate manually, helping identify patterns that may predict treatment response or resistance.
As these technologies mature, physicians will be better positioned to tailor treatment strategies not only to the tumor itself, but also to each patient’s unique immune landscape.
New Hope for Advanced Disease
Perhaps the greatest promise of next-generation personalized immunotherapy lies in patients with advanced or metastatic disease.
Historically, treatment options became increasingly limited as cancers progressed through multiple lines of therapy. While many challenges remain, innovative immunotherapies are beginning to offer new opportunities where conventional treatments have reached their limits.
Researchers are investigating combination approaches that integrate checkpoint inhibitors, vaccines, cell therapies, targeted therapies, and other immune-modulating agents to generate stronger and more durable anti-tumor responses.
These projects build on the reality that a single treatment is rarely enough to beat advanced cancer. Instead, success usually requires getting several different parts of the immune system to work together at the same time.
As our understanding of tumor biology improves, combination immunotherapy that pairs targeted cellular approaches with established treatments may become an increasingly personalized strategy rather than a standardized treatment algorithm.
Collaboration Is Driving Progress
None of these advances occur in isolation.
This speed of innovation is the result of a massive, joint effort across the industry and academia, bringing together biotech companies, research centers, doctors, regulators, and patient advocates.
Clinical trials have become more adaptive and biomarker-driven, enabling researchers to identify responsive patient populations earlier in development. Regulatory agencies have also demonstrated increasing flexibility in evaluating innovative therapies that address significant unmet medical needs while maintaining rigorous standards for safety and efficacy.
Most importantly, patients who join clinical trials make these breakthroughs possible, directly changing how we treat cancer today.
Looking Ahead
The next decade is unlikely to produce a single breakthrough that transforms every cancer. Instead, progress will come through thousands of incremental advances that collectively reshape how oncology is practiced.
Future cancer care will increasingly integrate genomics, immune profiling, artificial intelligence, real-world evidence, and next-generation cell therapies into more individualized treatment strategies. Physicians will have access to richer biological information, allowing therapies to be selected based not only on the characteristics of the tumor, but also on the patient’s immune system and likelihood of response.
While many scientific and clinical challenges remain, one principle has become increasingly clear: the immune system is no longer viewed simply as a bystander in cancer treatment. It has become one of oncology’s most powerful therapeutic tools when precisely targeted.
As researchers continue to unlock its potential, personalized cancer care will move beyond treating disease to mobilizing each patient’s own biology in increasingly precise and effective ways. For many patients, including those facing advanced breast cancer and other hard-to-treat solid tumors, this evolution represents more than scientific progress. It represents the possibility of expanding treatment options, improving outcomes, and continuing to redefine what is achievable in cancer care.
Author Bio
Dr. Williams is a seasoned biopharmaceutical executive with over 35 years of industry and academic expertise, including significant clinical management in multinational pharmaceutical companies. Dr. Williams has served as BriaCell’s President & CEO since Oct 2016.
Previously, Dr. Williams was appointed as VP of Exploratory Development at Incyte Corporation during 2005 – 2016. He facilitated entry of over 20 compounds into the clinic, including approvals for ruxolitinib (Jakafi) and baricitinib (Olumiant).
As VP of Clinical Pharmacology and Experimental Medicine at GlaxoSmithKline, Dr. Williams evaluated numerous molecules in clinical studies in various therapeutic areas. He was involved in new or supplemental drug authorizations for a number of oncology drugs including Bexxar (lymphoma), Hycamtin (ovarian cancer), and Navelbine (non-small cell lung cancer) as well as ibandronate (Boniva) for osteoporosis.
As Head of Rheumatology Research at the University of Pennsylvania, he ran a major research program in receptor biology, collaborated with David B. Weiner, PhD to develop DNA vaccines and was able to bring novel DNA vaccines into the clinic for the treatment of cutaneous T cell lymphoma.
Dr. Williams earned his BSc. in Chemistry and Biotechnology from MIT and Medical Doctorate from Tufts University School of Medicine. He has worked in the molecular immunology laboratory of Mark I. Greene, MD, PhD, FRCP, at the University of Pennsylvania, developed novel methods of bioactive peptide design, and collaborated in the study of the activation of the p185/Human epidermal growth factor receptor 2 (HER2) receptor. HER-2 is a protein which is known to promote the growth of cancer cells. Dr. Williams is the named author at over 130 peer reviewed publications, over 15 patents and numerous Investigational New Drugs (INDs) and NDAs.
